Alexander Keenan

428 total citations
20 papers, 252 citations indexed

About

Alexander Keenan is a scholar working on Psychiatry and Mental health, Pathology and Forensic Medicine and Economics and Econometrics. According to data from OpenAlex, Alexander Keenan has authored 20 papers receiving a total of 252 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Psychiatry and Mental health, 9 papers in Pathology and Forensic Medicine and 5 papers in Economics and Econometrics. Recurrent topics in Alexander Keenan's work include Multiple Sclerosis Research Studies (9 papers), Schizophrenia research and treatment (6 papers) and Health Systems, Economic Evaluations, Quality of Life (4 papers). Alexander Keenan is often cited by papers focused on Multiple Sclerosis Research Studies (9 papers), Schizophrenia research and treatment (6 papers) and Health Systems, Economic Evaluations, Quality of Life (4 papers). Alexander Keenan collaborates with scholars based in United States, Switzerland and United Kingdom. Alexander Keenan's co-authors include Sumeet Singh, Evelyn Worthington, Arun Singh, Srihari Gopal, Maju Mathews, Isaac Nuamah, Panna Sanga, Carmela Benson, Kruti Joshi and Dee Lin and has published in prestigious journals such as Journal of Alzheimer s Disease, BMJ Open and BMC Psychiatry.

In The Last Decade

Alexander Keenan

18 papers receiving 248 citations

Peers

Countries citing papers authored by Alexander Keenan

Since Specialization

Citations

This map shows the geographic impact of Alexander Keenan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alexander Keenan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alexander Keenan more than expected).

Fields of papers citing papers by Alexander Keenan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alexander Keenan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alexander Keenan. The network helps show where Alexander Keenan may publish in the future.

Co-authorship network of co-authors of Alexander Keenan

This figure shows the co-authorship network connecting the top 25 collaborators of Alexander Keenan. A scholar is included among the top collaborators of Alexander Keenan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alexander Keenan. Alexander Keenan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A systematic literature review of the association between global brain atrophy and the Expanded Disability Status Scale score in people with multiple sclerosis 2025 ·Therapeutic Advances in Neurological Disorders ·Robert Zivadinov, Hoa H. Le, Alexander Keenan, Susan Jill Stocks	1
2	Brain volume loss in relapsing multiple sclerosis: indirect treatment comparisons of available disease-modifying therapies 2024 ·BMC Neurology ·Robert Zivadinov, Alexander Keenan, Hoa H. Le, (unknown), Kavita Gandhi, Matthew L. Zierhut, (unknown), (unknown), (unknown), Sumeet Singh, Brian Hutton	2
3	Clinicians’ Preferences for Sphingosine-1-Phosphate Receptor Modulators in Multiple Sclerosis Based on Clinical Management Considerations: A Choice Experiment 2024 ·PharmacoEconomics - Open ·Alexander Keenan, Chiara Whichello, Hoa H. Le, David M. Kern, (unknown), (unknown), Anup Das, Matthew Quaife, Amy Perrin Ross	1
4	Shared Decision-Making in the Treatment of Multiple Sclerosis: Results of a Cross-Sectional, Real-World Survey in Europe and the United States 2024 ·Patient Preference and Adherence ·Alexander Keenan, Hoa H. Le, Kavita Gandhi, Lola Adedokun, Eddie Jones, (unknown), James Pike, (unknown)	1
5	Patients’ Preferences for Sphingosine-1-Phosphate Receptor Modulators in Multiple Sclerosis Based on Clinical Management Considerations: A Choice Experiment 2024 ·Patient ·Alexander Keenan, Chiara Whichello, Hoa H. Le, David M. Kern, (unknown), (unknown), Anup Das, Matthew Quaife, Amy Perrin Ross	2
6	Meaningful Change Thresholds and Fatigue Severity Points on Patient-Reported Outcomes by the Fatigue Symptoms and Impacts Questionnaire in Patients With Relapsing Multiple Sclerosis 2024 ·Value in Health ·Stacie Hudgens, Eva G. Katz, Evan Davies, Alexander Keenan, (unknown), Carol Jamieson	2
7	Severity and worsening of fatigue among individuals with multiple sclerosis 2023 ·Multiple Sclerosis Journal - Experimental Translational and Clinical ·Amber Salter, Alexander Keenan, Hoa H. Le, Kavita Gandhi, (unknown), Samantha Lancia, Gary Cutter, Robert J. Fox, Ruth Ann Marrie	6
8	Feasibility study to evaluate capabilities for conducting psychiatric clinical research within the Rwandan mental healthcare system 2023 ·BMJ Open ·Larry Alphs, Ibrahim Turkoz, Virginia L. Smith‐Swintosky, Alexander Keenan, (unknown), Alain Schotte, (unknown), (unknown), Yvonne Kayiteshonga, (unknown), Branislav Mancevski	0
9	Patient-psychiatrist discordance and drivers of prescribing long-acting injectable antipsychotics for schizophrenia management in the real-world: a point-in-time survey 2022 ·BMC Psychiatry ·Alexander Keenan, Dee Lin, Jason F. Shepherd, (unknown), Carmela Benson, Sophie Meakin	8
10	Comparing Relapse Rates in Real-World Patients with Schizophrenia Who Were Adequately versus Not Adequately Treated with Paliperidone Palmitate Once-Monthly Injections Before Transitioning to Once-Every-3-Months Injections 2022 ·Neuropsychiatric Disease and Treatment ·Ibrahim Turkoz, Mehmet Daskiran, H. Lynn Starr, Dean Najarian, (unknown), (unknown), Alexander Keenan, Carmela Benson, Srihari Gopal	2
11	Comparative Efficacy of Relapsing Multiple Sclerosis Therapies: Model-Based Meta-Analyses for Confirmed Disability Accumulation and Annualized Relapse Rate 2022 ·Multiple Sclerosis and Related Disorders ·Bryan T. Hennessy, Matthew L. Zierhut, Hilke Kracker, Alexander Keenan, (unknown)	3
12	POSB77 Comparing the Total Costs of Oral Disease Modifying Therapies for Patients with Active Relapsing Multiple Sclerosis in the US 2022 ·Value in Health ·(unknown), (unknown), (unknown), Alexander Keenan	1
13	Relapse and Treatment Adherence in Patients with Schizophrenia Switching from Paliperidone Palmitate Once-Monthly to Three-Monthly Formulation: A Retrospective Health Claims Database Analysis 2021 ·Patient Preference and Adherence ·Gang Li, Alexander Keenan, Mehmet Daskiran, Maju Mathews, Isaac Nuamah, Camille Orman, Kruti Joshi, Arun Singh, (unknown), (unknown), Srihari Gopal	17
14	Associations Between Relapses and Psychosocial Outcomes in Patients With Schizophrenia in Real-World Settings in the United States 2021 ·Frontiers in Psychiatry ·Dee Lin, Kruti Joshi, Alexander Keenan, Jason F. Shepherd, (unknown), (unknown), (unknown), Sophie Meakin, Carmela Benson, Edward Kim	20
15	Prevalence and burden of multiple sclerosis-related fatigue: a systematic literature review 2021 ·BMC Neurology ·(unknown), Alexander Keenan, (unknown), Evelyn Worthington, (unknown), Sumeet Singh	128
16	<p>Patients’ Preference for Long-Acting Injectable versus Oral Antipsychotics in Schizophrenia: Results from the Patient-Reported Medication Preference Questionnaire</p> 2020 ·Patient Preference and Adherence ·(unknown), Panna Sanga, Isaac Nuamah, Alexander Keenan, Arun Singh, Maju Mathews, Srihari Gopal	46
17	Ethical and Social Implications of Using Predictive Modeling for Alzheimer’s Disease Prevention: A Systematic Literature Review 2020 ·Journal of Alzheimer s Disease ·(unknown), (unknown), Clémentine Nordon, Andrew Turner, Dianne Gove, Hélène Karcher, Alexander Keenan, Brent Mittelstadt, (unknown)	7
18	PMH13 ESTIMATING THE BENEFIT OF LONG-ACTING INJECTABLES FOR SCHIZOPHRENIA TREATMENT IN RWANDA USING A ONE-YEAR COST-CONSEQUENCE MODEL 2019 ·Value in Health ·(unknown), Alexander Keenan, (unknown), (unknown), (unknown), Virginia L. Smith‐Swintosky, (unknown), Yvonne Kayiteshonga, (unknown), (unknown)	1
19	Ethical and social implications of using predictive modeling for Alzheimer’s disease prevention: a systematic literature review protocol 2019 ·BMJ Open ·(unknown), Clémentine Nordon, Andrew Turner, Dianne Gove, Hélène Karcher, Alexander Keenan, (unknown), (unknown), (unknown)	4
20	PMH67 USING REAL WORLD DATA TO PROFILE CURRENT STANDARD OF CARE FOR SCHIZOPHRENIA PATIENTS AT A MENTAL HEALTH HOSPITAL IN RWANDA, AFRICA 2019 ·Value in Health ·(unknown), (unknown), (unknown), Alexander Keenan, (unknown), Virginia L. Smith‐Swintosky, Yvonne Kayiteshonga, (unknown), (unknown)	0

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact